Natco Pharma Q2 Results Date FY27: 13 Nov Listed, Profit Base, Adcock Share and Rights Issue

Earnings · Pharma

The Natco Pharma Q2 results date is listed as Friday, 13 November 2026. Here are the year-ago base, the Q1 FY27 profit fall, the Adcock Ingram share of profit, the rights issue and the checks for results day.

Updated: Thursday, 12 November 2026, 11:50 AM IST  |  Reading time: 21 min  |  Next update: Friday, 13 November 2026 (listed), after the board meeting and filing

Latest update (Thursday, 12 November 2026, 11:50 AM IST): an Upstox results calendar updated on 8 November lists Natco Pharma for 13 November. TipRanks shows an estimated 17 November. I could not find the company’s board-meeting notice, a results time or published results at the time of writing.

In plain words: Natco Pharma is a Hyderabad drugmaker known for cancer medicines. It earns much of its profit from a few US generic launches, so one drug can swing a quarter, and it also owns a large stake in South Africa’s Adcock Ingram.

Data note: Figures are as of 12 November 2026, 11:50 AM IST. They follow Business Standard, Kotak Neo, Free Press Journal, Indian Pharma Post, InvestyWise, Multibagg and TipRanks. I could not open the exchange filings, so quarterly figures are headline-level. Derived numbers are my calculation. The consensus comes from one aggregator.

When is the Natco Pharma Q2 results date, and at what time will it be announced?

The Natco Pharma Q2 results date is listed as Friday, 13 November 2026 by Upstox, in a calendar updated on 8 November. TipRanks shows an estimated 17 November. I did not find the board notice or a results time.

The two dates come from third-party calendars, and neither is the company’s own notice. The Natco page I opened on Sharpely listed rights-issue filings up to 23 October 2026 but no board-meeting intimation for the results. Companies must report within 45 days of the quarter-end, which makes Saturday, 14 November the legal limit (my calculation), so 17 November would be late unless a different rule applies; that supports the 13 November listing. Last year Natco announced its Q2 results on Friday, 14 November 2025, and the Press Trust of India report was published at 2:14 pm that day. Q1 FY27 results were reported around 14 August 2026 (Kotak Neo).

Natco Pharma Q2 results date: what each source says

Cite this table: Results date status, as of 12 November 2026, 11:50 AM IST, PositionalCalls.

See the Q2 results hub for other reporters, and Alkem and Sun Pharma for other drugmakers.

Why the day matters for pharma investors

Q1 FY27 profit fell 57% as sales of the cancer drug lenalidomide shrank, so Q2 shows whether the base business and the Adcock stake can offset a much lower contribution from it (my reading, not a forecast).

What is the profit and revenue base Natco Pharma has to beat in Q2 FY27?

The Q2 FY26 base is consolidated net profit of Rs 517.9 crore, down 23.44% from Rs 676.5 crore, on revenue from operations of Rs 1,363 crore. Total expenses were Rs 849.3 crore against Rs 616.7 crore, per Business Standard.

Cite this table: Natco Pharma Q2 FY26 base per Business Standard; margins and changes calculated by PositionalCalls.

The sources differ on revenue. Business Standard and Angel One give revenue from operations of Rs 1,363 crore, while InvestyWise gives Rs 1,463 crore, which it labels consolidated total revenue and which includes Rs 104.3 crore of other operating and non-operating income. The two differ by Rs 100 crore, and the other-income line does not reconcile them exactly (my calculation), so I use Rs 1,363 crore as the base and treat Rs 1,463 crore as a wider measure. InvestyWise also reports EBITDA of Rs 679.2 crore at 46.4%, which includes other income. Angel One gives the reasons for the profit fall as higher research spending, bioequivalence study costs and a one-time employee bonus.

Why the base is so high

Q2 FY26 profit was 2.5 times Q1 FY27 profit (my calculation, Rs 517.9 crore against Rs 206.5 crore). Those are different quarters, so this is not a growth rate. It shows how high the base is compared with the latest quarter.

What did Natco Pharma report in Q1 FY27, the nearest mark?

In Q1 FY27 Natco Pharma reported consolidated net profit of Rs 206.5 crore, down 57%, and revenue of Rs 735 crore, down 44.7%, with EBITDA of Rs 186 crore at 25.3%. Kotak Neo attributes the fall mainly to lower lenalidomide sales.

Cite this table: Natco Pharma Q1 FY27 per Kotak Neo, Free Press Journal and Indian Pharma Post; ties checked by PositionalCalls.

These tie: Rs 186 crore on Rs 735 crore is 25.3%, and Rs 735 crore over Rs 1,329 crore is a 44.7% fall (my calculation). Net profit of Rs 206.5 crore includes Rs 84.3 crore of profit share from Adcock Ingram, so profit after tax before that share was Rs 122.2 crore, and the two add up (Indian Pharma Post). The Adcock share was 40.8% of net profit (my calculation). Indian Pharma Post gives total revenue of Rs 794.4 crore and EBITDA of Rs 245.7 crore at 30.9%, which include other income, so it differs from Kotak Neo’s Rs 735 crore and Rs 186 crore; the definitions differ.

Segments in Q1 FY27

Cite this table: Natco Pharma segment revenue per Kotak Neo and Indian Pharma Post; changes by PositionalCalls.

The drop is in international formulations, where lenalidomide sits; domestic formulations and API grew by more than a quarter each. The sources do not give lenalidomide revenue alone, so I cannot size its fall.

What has Natco Pharma done on capital and dividends, and could the Natco Pharma Q2 results date bring a dividend?

Natco Pharma declared an interim dividend of Rs 1.50 a share with Q1 FY27 and approved a rights issue of about Rs 1,300 crore at Rs 750 a share in a 2 for 21 ratio on 9 September 2026. No dividend is mentioned for the results meeting.

Cite this table: Natco Pharma capital and dividend record; derived figures by PositionalCalls.

The size has two figures: Multibagg’s text says Rs 1,300 crore while a headline on the same page says Rs 1,279 crore. My calculation gives about Rs 1,279 crore from about 17.91 crore shares, taken from profit and earnings per share, so the Rs 1,300 crore figure may be rounded or an upper limit; I could not confirm. Exchange filings show an allotment of equity shares on 23 October 2026, but I did not confirm that it was the rights allotment. A larger share count would lower earnings per share for the same profit, so check how the company treats it.

See dividend tax in India for how dividends are taxed.

What has Natco Pharma said about growth, pipeline and Adcock Ingram?

The sources I opened give no numeric guidance. Indian Pharma Post lists 28 Para IV filings, more than 20 first-to-file opportunities and 17 approved products, plus final US FDA approval for Eribulin Mesylate Injection, and Natco’s Adcock Ingram stake rising from 35.75% to 49%.

Cite this table: Natco Pharma pipeline and associate details per Indian Pharma Post; not verified against filings.

The Indian Pharma Post article also lists the Bidvest stake at 64.25% beside Natco’s old 35.75%, which cannot hold after the rise to 49%, so treat that line as out of date. Sahi reports a domestic-growth target in an August item whose body I did not open, so I give no figure for it.

What drives Natco Pharma’s Q2 numbers: lenalidomide, domestic sales and Adcock?

Four lines drive the quarter: international formulations, which hold the cancer generics, the growth in domestic formulations and API, research spending, and the profit share from Adcock Ingram. In Q1 FY27 the Adcock share was Rs 84.3 crore of Rs 206.5 crore profit.

Cite this table: Natco Pharma driver checklist, PositionalCalls; figures from the sources above.

Items to check in the filing

• Revenue against Rs 1,363 crore and Rs 735 crore.
• Consolidated net profit against Rs 517.9 crore and Rs 206.5 crore.
• The Adcock Ingram profit share and the one-off lines.
• Earnings per share and any change for the rights issue.
• Any dividend announcement and its record date.

A note on the numbers

Net profit in Q1 FY27 was 28.1% of revenue (my calculation, Rs 206.5 crore on Rs 735 crore) against 38.0% in Q2 FY26, but the Q1 profit includes an associate share that is not part of revenue, so the ratio is a rough guide only.

What would different Natco Pharma Q2 outcomes look like in numbers?

If Q2 revenue stays at the Q1 level of Rs 735 crore and the profit margin stays at 28.1%, profit would be about Rs 206.5 crore, 60.1% below the Rs 517.9 crore base. These are arithmetic illustrations, not forecasts.

Cite this table: Natco Pharma Q2 FY27 arithmetic, my calculation. Margins are Q1 FY27 and Q2 FY26 net margins. Not forecasts.

Cite this table: Natco Pharma Q2 FY27 profit arithmetic, my calculation. Levels are illustrations, not forecasts.

Three worked examples

Example 1, Q1 repeated. Revenue of Rs 735 crore at a 28.1% margin gives profit of about Rs 206.5 crore, 60.1% below the base (my calculation).

Example 2, partial recovery. Revenue of Rs 1,100 crore at 28.1% gives about Rs 309.1 crore, 40.3% below the base.

Example 3, base matched. A profit of Rs 517.9 crore would need revenue near Rs 1,363 crore at the Q2 FY26 margin of 38.0%, which is 85.4% above Q1 revenue (my calculation).

How do I read the Natco Pharma results on results day?

On results day read, in this order: revenue against Rs 1,363 crore and Rs 735 crore, consolidated net profit against Rs 517.9 crore and Rs 206.5 crore, the Adcock share, then expenses, earnings per share and any dividend.

Cite this table: Natco Pharma results-day reading order, PositionalCalls.

Compare like with like: use revenue from operations against revenue from operations, and say whether EBITDA includes other income.

How do I read the Natco Pharma filing and avoid fake alerts?

On results day, open the NSE or BSE announcement for Natco Pharma Limited, not a link in a message, and read the results table first. Treat any tip that asks for an OTP, payment or login as fake.

1. Open the exchange announcement page for Natco Pharma Limited.
2. Read the unaudited results for the quarter ended 30 September 2026.
3. Note revenue, expenses and consolidated net profit.
4. Compare with Rs 1,363 crore, Rs 849.3 crore and Rs 517.9 crore.
5. Read the notes for the Adcock share and exceptional items.
6. Check any dividend announcement and its record date.

PositionalCalls is not SEBI-registered, gives no buy or sell calls and never asks for payment. Nothing here is investment advice.

What do most people miss about the Natco Pharma Q2 results?

Around the Natco Pharma Q2 results date, most readers miss that the date is only listed, that Adcock supplied about 41% of Q1 profit, that revenue has two figures and that a rights issue may change earnings per share.

A last point on sources. Several figures here come from news reports and aggregators, and these can differ from the filing: revenue for Q2 FY26 is Rs 1,363 crore in one place and Rs 1,463 crore in another, and Q1 FY27 revenue is Rs 735 crore or Rs 794.4 crore. Before using any number in a decision, open the exchange filing, check the definition of each line and note the date of the report. I list each source with its date below so the comparison can be repeated.

Another habit worth keeping is to write down the three or four numbers you care about before the filing appears, such as revenue, profit and expenses, so you can read the result against your own checklist and not against the headline. Headlines tend to pick the largest percentage change, which can look dramatic after a one-off quarter. The rupee figure and the base it is measured against tell the fuller story.

If a figure on this page changes after the filing, the Updated date at the top will change too, and the Latest update line will say what moved. Previews like this one are converted into results pages once the numbers are out, so the comparison tables are kept and the year-ago base stays visible next to the new figures.

Drugmakers that depend on a few generic launches can see large swings: a quarter with a strong launch can double profit, and a quarter after it fades can halve it. Reading international sales, the domestic business and the associate share separately gives a steadier picture than any one headline number alone.

Natco Pharma Q2 results date: frequently asked questions

Sources

• NSE India: corporate announcements: where the results will appear.
• BSE India: corporate announcements: the results filing.
• Upstox: upcoming Q2 FY27 results list, updated 8 November 2026.
• TipRanks: Natco Pharma earnings: estimated date and consensus EPS.
• Kotak Neo: Natco Pharma Q1 FY27 results, August 2026.
• Indian Pharma Post: Natco Pharma Q1 FY27, 2026.
• Business Standard: Natco Pharma Q2 FY26, 14 November 2025.
• InvestyWise: Natco Pharma Q2 FY26 revenue, 14 November 2025.
• Multibagg: Natco Pharma AGM and rights issue, September 2026.

Disclosure: PositionalCalls.com is not a SEBI-registered research analyst or investment adviser. Investments in securities markets are subject to market risks. Read all related documents carefully before investing. Returns are never guaranteed. PositionalCalls is an independent research and education site founded by Shubham Chaudhary. Nothing here is a recommendation, target or investment advice. How I researched this: for the Natco Pharma Q2 results date I read Business Standard, Kotak Neo, Indian Pharma Post, InvestyWise, Multibagg, Upstox and TipRanks, noted where sources differ, and marked every derived number as my calculation. I did not open any company filing or exchange document. Figures are as of 12 November 2026, 11:50 AM IST.